MedWatch

Janssen sees USD 12bn sales potential in Genmab-developed drugs

Three potential candidates from Genmab have a USD 4bn top sales potential each, says Head of the Global Oncology Therapeutic Area at Janssen Peter Lebowitz.

Photo: BRENDAN MCDERMID/REUTERS / X90143

Genmab is already bringing in most of its top line revenue from partner Johnson & Johnson's sales of Darzalex, which is a Genmab-developed drug, but revenue streams from Johnson & Johnson's pharmaceutical arm could be considerably increased in the future, reports Danish business daily Børsen.

In a presentation, Peter Lebowitz, head of the Global Oncology Therapeutic Area at Janssen, says that six more portfolio candidates could see approvals or submissions for approvals before the end of 2023 – three of which are potential candidates developed by Genmab.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs